Abbott Laboratories
NYSE:ABT
Net Margin
Abbott Laboratories
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Abbott Laboratories
NYSE:ABT
|
219.3B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
181.3B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.8B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.3B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
66.1B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.6B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.8B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
293.4B CNY |
33%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37B USD |
10%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
34.1B USD |
23%
|
Abbott Laboratories
Glance View
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Abbott Laboratories's most recent financial statements, the company has Net Margin of 32%.
You don't have any saved screeners yet